HCC Patient Preferences in Japan

Bayer

Status: Completed

Conditions: Hepatocellular Cancer

Treatments: Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]

Study type: Observational

Funder types: Industry

Identifiers

NCT02616692

18234

Details and patient eligibility

About

This non-interventional cross-sectional online survey will evaluate preferences among patients with self-reported HCC. The survey will ask patients to express their preferences regarding descriptions of HCC treatments, which will include sorafenib (which will be described as 'oral anti-cancer therapy'), repeated transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). Please note that all interventions that patients may have received before completing this online survey were given regardless of their participation in this survey. Questions also include asking patients to rank various treatment characteristics (e.g., mechanism of action, risk of adverse effects, etc.) relative to each other. The ultimate goal is to better understand patient perceptions of these treatments and to provide evidence to help in patients' and physicians' treatment decision-making in HCC.

Enrollment: 120 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

The following eligibility criteria will be used:

• Have a diagnosis of HCC
• Are > 20 years of age
• Reside in Japan
• Are able to read and understand Japanese to provide informed consent and complete the survey instrument

Exclusion criteria

None are currently considered

Trial design

120 participants in 1 patient group

HCC patients / Cohort 1

Description:

Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics

Treatment:

Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]